Loading…
← CockpitCompetitor Analysis › 6949.TW PELL Bio-Med Technology Co LtdOpen in the cockpit ↗

PELL Bio-Med Technology Co Ltd6949.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology

Taiwanese biotech developing biomedical/regenerative-medicine products; specific pipeline and commercial products unconfirmed.

Momentum leader 90
Mkt cap
$1.62B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$6.84M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-23.9 pp
WACC 8.6%
Hurdle
n/a
no reverse DCF
Close · TWDNT$45.05
1D-0.7%
1W+0.7%
1M+15.8%
3M-6.0%
6M+28.4%
YTD+163.1%
1Y+156.0%
ATR %8.8%
52w lowhigh45.0% off high

What PELL Bio-Med Technology does

Taiwanese biotech developing biomedical/regenerative-medicine products; specific pipeline and commercial products unconfirmed.

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Biomedical product development

Moat: none

Headquarters: Taiwan

PELL Bio-Med Technology at a glance

Size PELL Bio-Med Technology (6949.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $1.62B, the 192nd largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$45.05 on 18 Nov 2026.

Performance Over six months the shares gained 28.4%, against -11.9% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 20 in its peer set.

Growth Revenue grew 7.8% over the last twelve months (peer median +24.9%); the operating margin is -1,463.2% (peer median 7.6%).

Valuation It trades at 1,650.2× enterprise value to sales against a peer median of 11.7× (most expensive of 18).

Capital Return on invested capital runs 23.9 points below its cost of capital (8.6% WACC).

Relative performance

10015020021 May 202621 Aug 202618 Nov 20266949.TW 132Peer median 90
Six months, rebased to 100: PELL Bio-Med Technology against the median of its 20 peers (local-currency closes).

PELL Bio-Med Technology financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$32.3MNT$31.4MNT$19.6MNT$18.0MNT$17.2M
Revenue growth—+60%+9%+5%—
Gross profit-NT$5.62M-NT$51.5M-NT$59.2M-NT$71.8M-NT$42.3M
EBITDAn/a-NT$420M-NT$367M-NT$366M-NT$205M
Net income-NT$420M-NT$424M-NT$389M-NT$399M-NT$230M
Free cash flown/a-NT$508M-NT$524M-NT$196M-NT$162M
Capital expendituren/aNT$247MNT$285MNT$16.5MNT$8.49M
Total debtn/aNT$237MNT$365MNT$173MNT$203M

Quarterly statements and history in the cockpit →

PELL Bio-Med Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%688222ALVOANIPPPGN600226VIR145020NRIXPGENKLRAKRSASTOKRXRX0870106880462637ZBIO6949.TW6-month return →1-month return →
Up and to the right = strong over both horizons. PELL Bio-Med Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×500×1,000×1,500×688222ALVOVIRNRIXPGENKRSA087010MSBZBIO6949.TWRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PELL Bio-Med Technology is the large dot.

PELL Bio-Med Technology competitors and peer comparison

How PELL Bio-Med Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PELL Bio-Med Technology against its 20 peers (data as of 18 Nov 2026)
Measure6949.TWPeer medianRank in peer set
1-month return+15.8%-8.0%highest of 21
6-month return+28.4%-11.9%5th highest of 20
Distance from 52-week high-45.0%-42.4%9th lowest of 21
Revenue growth (TTM)+7.8%+24.9%6th lowest of 19
Operating margin-1,463.2%7.6%3rd lowest of 19
EV / Sales1,650.2×11.7×most expensive of 18
ROIC minus cost of capital-23.9 pp-4.0 pp5th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%1,650.2×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%14.4×33.2%+16.8%
Alvotech ALVOUnited States$1.62B+38%-14%12%6.4×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%1.7×-7.6%+33.5%
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%3.4×n/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%4.2×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%4.0×n/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%3.6×-12.1%+15.0%
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%50.6×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%18.8×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%11.7×33.0%+24.8%
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a

Questions

Which companies are PELL Bio-Med Technology's closest peers?
The cockpit's peer set: Hitgen (688222.SS), Alvotech (ALVO), ANI Pharmaceuticals (ANIP), PolyPeptide (PPGN.SW), Zhejiang Hengtong (600226.SS), Vir Biotechnology (VIR), Hugel (145020.KS), Nurix Therapeutics (NRIX).
Is PELL Bio-Med Technology expensive compared with its peers?
On ev / sales it trades at 1,650.2× against a peer median of 11.7×, most expensive of 18 in its peer set.
How has PELL Bio-Med Technology stock performed?
Over six months to 18 Nov 2026 the shares returned +28.4% against -11.9% for the median peer; over one year +156.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.